|
. .  
|
Faculty
Research InterestsMolecular profiling of ovarian epithelial tumors using Affymetrix gene chip and proteomics technologies - Identification and characterization of molecular markers of ovarian carcinomas - Identification of novel genes amplified in ovarian carcinomas - Evaluation of the role of Wnt/beta-catenin/Tcf pathway defects in the pathogenesis of ovarian endometrioid adenocarcinomas - Identification of genes involved in cervical cancer progression EducationSept 1976- May 1980 Yale University, New Haven, Connecticut; B.A. (Chemistry) Aug 1980-May 1984 Vanderbilt University School of Medicine, Nashville, Tennessee; M.D. Postgraduate TrainingJuly 1984-June 1985 Intern, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland July 1985-June 1987 Assistant Resident, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland July 1987-June 1988 Chief Resident, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland July 1988-June 1990 Clinical Fellow, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland July 1988-Nov 1991Research Fellow, Laboratory of Bert Vogelstein, The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland Honors and Awards1980 B.A., magna cum laude, with distinction in Chemistry, Yale University. 1980 Howard Douglass Moore Prize for excellence in the field of Chemistry, Yale University. 1983 Alpha Omega Alpha, Vanderbilt University School of Medicine. 1984 Janet M. Glasgow Memorial Achievement Citation, Vanderbilt University School of Medicine. 2000 American Society for Clinical Investigation 2000 American Association of University Pathologists Recent PublicationsWu, R., Zhai, Y., Fearon, E.R., and Cho, K.R. Diverse Mechanisms of bβ -catenin Deregulation in Ovarian Endometrioid Adenocarcinomas. Cancer Research 61:8247-8255, 2001. Zhai, Y., Wu, R., Schwartz, D.R., Darrah, D., Kolligs,F.T., Nieman, M.T., Fearon E.R., and Cho, K.R. Role of b-catenin/TCF Regulated Genes in Ovarian Endometrioid Adenocarcinomas. American Journal of Pathology 160:1229-38, 2002. Kolligs, F.T., Nieman, M.N., Winer, I., Hu, G., van Mater, D.S., Feng, Y., Smith, I.M., Wu, R., Zhai, Y., Cho, K.R., and Fearon, E.R. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with b-catenin defects and promotes neoplastic transformation. Cancer Cell, 1:145-155, 2002. Schwartz, D.R., Kardia, S.L.R., Shedden, K.A., Kuick, R., Michailidis, G., Taylor, J.M.G., Misek, D.E., Wu, R., Zhai,Y., Darrah, D.M., Reed, H., Ellenson, L.H., Giordano, T.J., Fearon, E.R., Hanash, S.M., and Cho, K.R. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Research 62:4722-4729, 2002. Shedden, K.A., Kshirsagar, M.P., Schwartz, D.R., Wu, R., Yu, H., Misek, D.E., Hanash, S., Katabuchi, H., Ellenson, L.H., and Cho, K.R. Histological type, organ of origin, and Wnt pathway status: Impact on gene expression profile in ovarian and uterine carcinomas. Clinical Cancer Research 11:2123-31, 2005. CVs from interested candidates can be forwarded to kathcho@umich.edu Additional Lab LinksLab MembersBetty Pang, Undergraduate Student
|
||||||
|
|||||||
